Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.


Recent & Breaking News (OTCQB:RGRX)

RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome

PR Newswire May 14, 2021

RegeneRx Issues Update on ARISE-3 Trial

PR Newswire March 22, 2021

RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial

PR Newswire March 18, 2021

RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial

PR Newswire February 24, 2021

RegeneRx Comments on ARISE-3 Clinical Trial

PR Newswire January 26, 2021

RegeneRx Issues Year End Letter To Stockholders

PR Newswire December 21, 2020

Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trial

PR Newswire November 9, 2020

RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial

PR Newswire October 28, 2020

RegeneRx Closes Convertible Debt Financing

PR Newswire October 21, 2020

ARISE-3 Phase 3 Trial Completion Expected by End of 2020

PR Newswire October 14, 2020

RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome

PR Newswire October 12, 2020

New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19

PR Newswire September 8, 2020

RegeneRx Joint Venture Expects to Complete Phase 3 Dry Eye Trial in November 2020

PR Newswire August 31, 2020

RegeneRx Issues Update on Phase 3 Dry Eye Trial

PR Newswire August 19, 2020

RegeneRx Advisory on ARISE-3 Dry Eye Trial

PR Newswire June 2, 2020

RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic

PR Newswire May 27, 2020

RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259

PR Newswire May 14, 2020

RegeneRx Issues Advisory on ARISE-3 Dry Eye Trial

PR Newswire April 20, 2020

New Publication Describes Mechanism of Action for T?4 in Corneal Wound Healing and Regeneration

PR Newswire April 2, 2020

RegeneRx Issues Advisory on Dry Eye Trial Amid COVID-19 Virus

PR Newswire March 18, 2020